Chongqing Taiji Industry(Group)Ltd Third Quarter 2024 Earnings: EPS: CN¥0.091 (vs CN¥0.34 in 3Q 2023)

Simply Wall St · 10/25 22:23

Chongqing Taiji Industry(Group)Ltd (SHSE:600129) Third Quarter 2024 Results

Key Financial Results

  • Revenue: CN¥2.62b (down 16% from 3Q 2023).
  • Net income: CN¥50.5m (down 74% from 3Q 2023).
  • Profit margin: 1.9% (down from 6.2% in 3Q 2023). The decrease in margin was driven by lower revenue.
  • EPS: CN¥0.091 (down from CN¥0.34 in 3Q 2023).
earnings-and-revenue-growth
SHSE:600129 Earnings and Revenue Growth October 25th 2024

All figures shown in the chart above are for the trailing 12 month (TTM) period

Chongqing Taiji Industry(Group)Ltd Earnings Insights

Looking ahead, revenue is forecast to grow 15% p.a. on average during the next 3 years, compared to a 12% growth forecast for the Pharmaceuticals industry in China.

Performance of the Chinese Pharmaceuticals industry.

The company's shares are up 1.8% from a week ago.

Risk Analysis

You should learn about the 2 warning signs we've spotted with Chongqing Taiji Industry(Group)Ltd (including 1 which is a bit unpleasant).